LungLifeAI Logo

News & Updates

Our Purpose:
To be a driving force in the early detection of lung cancer.

May 15, 2024

Block Listing Six Monthly Return

LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: Name of applicant: LungLife AI, Inc. […]
• Read More
April 25, 2024

Publication of Annual Report and Accounts & Notice of AGM

LungLife AI, Inc.(the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now available on the Company’s […]
• Read More
April 17, 2024

LungLife to present at US National Cancer Institute’s Early Detection Research Network Meeting

LungLife AI, Inc.(the “Company” or “LungLife”) LungLife to present at US National Cancer Institute’s Early Detection Research Network Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces it has been invited to present at the National Cancer Institute’s (“NCI”) Early Detection Research Network (“EDRN”) meeting […]
• Read More
April 4, 2024

Preliminary audited results for year ended 31 December 2023

LungLife AI, Inc.(the “Company” or “LungLife”) Preliminary audited results for year ended 31 December 2023 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its audited preliminary results for the year ended 31 December 2023. Summary and Highlights for the year and post-period end: Commenting, Paul Pagano, Chief Executive Officer […]
• Read More
March 27, 2024

Notice of Results

LungLife AI Inc (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2023 on Thursday 4 April 2024. Investor presentation Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial […]
• Read More
March 22, 2024

Admission of New Shares and PDMR Dealing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN […]
• Read More
March 21, 2024

Result of Special Meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN […]
• Read More
1 2 3 7

Investor inquiries

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down